| Literature DB >> 30613412 |
Masatoshi Minamisawa1, Jun Koyama1, Ayako Kozuka1, Takashi Miura1, Tatsuya Saigusa1, Soichiro Ebisawa1, Hirohiko Motoki1, Ayako Okada1, Uichi Ikeda1, Koichiro Kuwahara1.
Abstract
Objective: Myocardial early systolic lengthening (ESL) duration is prolonged in patients with coronary artery disease (CAD). However, the relationship between the fractional flow reserve (FFR), the current gold standard for evaluating physiological myocardial ischaemia, and ESL has not been studied. The aims of this study were to investigate whether left ventricular (LV) ESL duration could identify patients with CAD, and to examine the relationship between FFR and LV ESL duration.Entities:
Keywords: fractional flow reserve; myocardial ischaemia; speckle tracking echocardiography
Year: 2018 PMID: 30613412 PMCID: PMC6307609 DOI: 10.1136/openhrt-2018-000896
Source DB: PubMed Journal: Open Heart ISSN: 2053-3624
Figure 1Representative example of LV early systolic lengthening duration using two-dimensional speckle tracking echocardiography (A) and 18-LV segment model (B). LAD, left anterior descending coronary artery; LCX, left circumflex; LV ESL, left ventricular early systolic lengthening; RCA, right coronary artery.
Patient clinical characteristics and echocardiographic findings
| Variable | nsCAD | CAD | P values | |
| (n=35) | FFR≥0.8 (n=17) | FFR<0.8 (n=23) | ||
| Age | 65±13 | 71±9* | 72±7* | 0.04 |
| Male/female | 18/17 | 6/11 | 15/8 | 0.17 |
| Systolic blood pressure (mm Hg) | 130±19 | 139±22 | 129±16 | 0.23 |
| Diastolic blood pressure (mm Hg) | 76±10 | 76±16 | 75±10 | 0.95 |
| Heart rate (beats/min) | 63±10 | 62±8 | 64±7 | 0.82 |
| Hypertension, n (%) | 27 (77) | 11 (65) | 17 (74) | 0.63 |
| Dyslipidaemia, n (%) | 20 (57) | 13 (77) | 17 (74) | 0.26 |
| Diabetes mellitus, n (%) | 18 (51) | 8 (47) | 11 (48) | 0.94 |
| Smoking, n (%) | 13 (37) | 5 (29) | 17 (74)* | 0.02 |
| Multivessel disease, n (%) | 6 (35) | 10 (44) | 0.21 | |
| Visual stenosis, n (50%/75%/>90%) | 2/4/11 | 1/9/13 | 0.38 | |
| Aspirin/other antiplatelet medication, n (%) | 13 (37) | 16 (94)* | 23 (100)* | <0.01 |
| ACE inhibitor/ARB, n (%) | 17 (49) | 9 (53) | 17 (74) | 0.15 |
| Beta-blocker, n (%) | 4 (11) | 4 (24) | 6 (26) | 0.26 |
| Statin, n (%) | 16 (46) | 12 (71)* | 18 (78)* | 0.03 |
| Haemoglobin (g/L) | 1.35±0.19 | 1.34±0.18 | 1.34±0.14 | 0.90 |
| LDL-C (mg/dL) | 110±33 | 96±33 | 100±31 | 0.30 |
| Haemoglobin A1c (%) | 6.4±1.0 | 6.3±0.9 | 6.4±0.9 | 0.95 |
| BNP (pg/mL) | 24.4 (15.2, 43.3) | 25.6 (14.3, 55.1) | 28.9 (16.3, 53.2) | 0.95 |
| Echocardiographic findings | ||||
| Left atrial diameter (cm) | 3.9±0.6 | 4.0±0.7 | 4.0±0.7 | 0.70 |
| LV thickness (septum) (cm) | 1.1±0.2 | 1.2±0.3 | 1.1±0.2 | 0.28 |
| LV thickness (posterior) (cm) | 1.1±0.2 | 1.1±0.2 | 1.1±0.1 | 0.84 |
| LV end-diastolic diameter (cm) | 4.7±0.5 | 4.8±0.7 | 4.7±0.4 | 0.88 |
| LV end-systolic diameter (cm) | 2.6±0.5 | 2.8±0.6 | 2.6±0.4 | 0.59 |
| LV end-diastolic volume index (mL/m2) | 36±11 | 38±11 | 34±10 | 0.55 |
| LV end-systolic volume index (mL/m2) | 12±6 | 12±5 | 12±5 | 0.91 |
| LV ejection fraction (%) | 65±6 | 68±7 | 66±9 | 0.41 |
| Transmitral flow | ||||
| Peak E velocity (m/s) | 0.63±0.17 | 0.65±0.13 | 0.74±0.15* | 0.044 |
| Peak A velocity (m/s) | 0.78±0.16 | 0.87±0.13 | 0.90±0.16* | 0.04 |
| E/A | 0.82±0.23 | 0.76±0.15 | 0.84±0.22 | 0.50 |
| Deceleration time (ms) | 220±65 | 264±77 | 221±53 | 0.11 |
| Pulmonary venous flow | ||||
| Peak S velocity (m/s) | 0.58±0.11 | 0.54±0.14 | 0.64±0.15 | 0.06 |
| Peak D velocity (m/s) | 0.41±0.08 | 0.36±0.08 | 0.44±0.12† | 0.04 |
| Peak A velocity (m/s) | 0.27±0.06 | 0.27±0.05 | 0.30±0.06 | 0.13 |
| Mitral annulus TDI | ||||
| e′ (septum) (cm/s) | 6.5±2.6 | 5.4±1.2 | 6.7±1.7 | 0.11 |
| e′ (lateral) (cm/s) | 8.1±2.7 | 7.2±1.7 | 8.0±1.8 | 0.44 |
| E/e′ (septum) | 10.7±4.5 | 12.9±3.8 | 11.5±2.7 | 0.17 |
| E/e′ (lateral) | 8.5±3.5 | 9.6±3.1 | 9.5±2.3 | 0.33 |
Values are number (%), mean ± standard deviation, or median (25th, 75th percentiles).
*P<0.05 versus nsCAD group.
†P<0.05 versus FFR>0.8 group.
ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; CAD, coronary artery disease; FFR, fractional flow reserve; LDL, low density lipoprotein cholesterol; LV, left ventricular; TDI, tissue Doppler imaging; e′, peak early diastolic velocity of the mitral annulus; nsCAD, non-significant coronary artery disease.
Figure 2Myocardial deformation in patients with and without coronary artery disease measured by LV GLS levels (A), postsystolic shortening (B), LV peak positive early strain (C), and duration of LV ESL (D). The bottom and top whiskers indicate the fifth and 95th percentile levels, respectively; the lower and upper boundaries of the boxes, the 25th and 75th percentile levels, respectively; and the horizontal line within the box, the median level. CAD, coronary artery disease; FFR, fractional flow reserve; LV ESL, left ventricular early systolic lengthening; LV GLS, left ventricular global longitudinal strain; nsCAD, non-significant coronary artery disease.
Regional speckle tracking echocardiographic findings
| Variable | nsCAD | CAD | P values | |
| (n=35) | FFR≥0.8 (n=17) | FFR<0.8 (n=23) | ||
| Left anterior descending territories | n=35 | n=8 | n=15 | |
| LV longitudinal strain (%) | −16.4 (−14.7, −18.6) | −16.3 (−15.2, −18.2) | −13.9 (−12.9, −17.2) | 0.22 |
| Postsystolic shortening (%) | −0.76 (−0.25, −1.10) | −0.26 (0, −1.5) | −0.32 (−0.058, −1.27) | 0.67 |
| LV peak positive early strain (%) | 0.58 (0.23, 0.84) | 0.73 (0.17, 1.03) | 0.83 (0.61, 1.08) | 0.31 |
| Duration of LV ESL (ms) | 20.9 (11.0, 34.2) | 23.1 (8.5, 36.0) | 46.4 (33.8, 59.0)*† | 0.01 |
| Left circumflex and right coronary artery territories | n=35 | n=9 | n=8 | |
| LV longitudinal strain (%) | −17.5 (−16.8, −19.0) | −16.3 (−15.2, −18.2) | −17.5 (−16.5, −19.5) | 0.27 |
| Postsystolic shortening (%) | −0.47 (−0.23, −0.81) | −0.58 (−0.32, −0.99) | −0.32 (−0.034, −0.69) | 0.30 |
| LV peak positive early strain (%) | 0.72 (0.58, 1.25) | 1.36 (0.58, 1.79) | 0.92 (0.57, 1.91) | 0.21 |
| Duration of LV ESL (ms) | 27.1 (15.2, 40.8) | 53.8 (19.8, 65.2) | 37.0 (28.2, 55.9) | 0.05 |
Values are median (25th, 75th percentiles).
*P<0.05 versus nsCAD group.
†P<0.05 versus FFR>0.8 group.
CAD, coronary artery disease; ESL, early systolic lengthening; FFR, fractional flow reserve; LV, left ventricular; nsCAD, non-significant coronary artery disease.
Figure 3Correlation between fractional flow reserve and duration of (A) global LV ESL, (B) regional LV ESL, (C) regional LV ESL (first three longest segments) in the LAD, and (D) regional LV ESL (first three longest segments) in non-LAD. DESL, duration of ESL; ESL, early systolic lengthening; LAD, left anterior descending coronary artery; LV, left ventricular.
Logistic regression analyses of predictors of coronary artery disease
| Univariate | Multivariate | |||
| OR (95% CI) | P values | OR (95% CI) | P values | |
| Age | 1.06 (1.01 to 1.11) | 0.01 | 1.06 (1.01 to 1.17) | 0.02 |
| Sex, female | 0.96 (0.39 to 2.38) | 0.92 | ||
| Systolic blood pressure | 1.01 (0.99 to 1.04) | 0.38 | ||
| Hypertension | 0.69 (0.25 to 1.95) | 0.45 | ||
| Dyslipidaemia | 2.25 (0.84 to 6.00) | 0.11 | ||
| Diabetes mellitus | 0.83 (0.35 to 2.11) | 0.73 | ||
| Smoking | 1.75 (0.83 to 3.69) | 0.14 | ||
| Multivessel disease | 1.11 (0.86 to 2.32) | 0.65 | ||
| BNP | 1.01 (0.99 to 1.01) | 0.88 | ||
| LV ejection fraction | 1.03 (0.97 to 1.10) | 0.34 | ||
| LV GLS | 1.09 (0.87 to 1.35) | 0.46 | ||
| Postsystolic shortening | 1.00 (0.36 to 2.80) | 0.99 | ||
| LV peak positive early strain | 1.96 (0.78 to 4.85) | 0.15 | ||
| Duration of LV early systolic lengthening | 1.03 (1.01 to 1.05) | 0.0060 | 1.03 (1.01 to 1.05) | 0.010 |
BNP, B-type natriuretic peptide; GLS, global longitudinal strain;
LV, left ventricular.
Figure 4Receiver operating characteristic (ROC) curves for detecting (A) patients with coronary artery disease and (B) patients with FFR<0.8 in global measurements. The AUC for duration of LV ESL was the highest, with optimal ROC cut-off points of 13.4 ms (A) and 21.2 ms (B), respectively. AUC, area under the ROC curve; FFR, fractional flow reserve; LV ESL, left ventricular early systolic lengthening; LV GLS, left ventricular global longitudinal strain; PSS, postsystolic shortening.
Intrarobserver and interobserver reproducibility of speckle tracking echocardiography data
| Intraobserver | Interobserver | |||
| Bias and limits of agreement (%) | CV (%) | Bias and limits of agreement (%) | CV (%) | |
| Global measurements | ||||
| LV GLS | 0.45±0.62 | 2.14 | 0.36±0.63 | 2.30 |
| LV peak positive early strain | 0.29±0.40 | 23.57 | 0.31±0.43 | 24.03 |
| Duration of LV ESL | 7.34±10.18 | 7.91 | 10.20±14.13 | 12.75 |
| Regional measurements of LV ESL duration | ||||
| Apical four-chamber view | 12.31±17.04 | 16.07 | 4.90±6.79 | 16.80 |
| Apical two-chamber view | 8.42±11.64 | 9.85 | 13.63±18.84 | 15.99 |
| Apical long-axis view | 8.54±11.78 | 9.98 | 16.95±23.42 | 24.71 |
CV, coefficient of variation; ESL, early systolic lengthening; GLS, global longitudinal strain; LV, left ventricular.